Literature DB >> 2459235

IFN-treated neuroblastoma cell lines remain resistant to T cell-mediated allo-killing, and susceptible to non-MHC-restricted cytotoxicity.

E K Main1, D S Monos, L A Lampson.   

Abstract

Neuroblastoma cell lines can have very low MHC Ag expression. The cell lines are insensitive to allo-killing by primed CTL, but are sensitive to non-MHC-restricted cytotoxicity. IFN-gamma increased class I expression, but the cells remained insensitive to CTL. Susceptibility to nonrestricted effectors was preserved. Class I+ glioma cell lines behaved similarly. The CTL resistance was localized to the recognition phase. Neuroblastoma lines did not form conjugates with primed T cells, but were lysed if they were coupled to the effectors via lectins. The levels of class I expression, and resistance to CTL, were constant over a range of IFN doses. HLA-A,B,C structure and distribution were studied more intensively on one cell line, CHP-100. HLA-A2 and -A3 were present on greater than or equal to 99% of the cells, in a unimodal distribution. After IFN treatment, the levels were similar to B cell controls. In two-dimensional gel electrophoresis, the molecules co-migrated with those of B cell controls. The defect may thus be in accessory proteins that are necessary for T cell recognition or binding, rather than in the structure or distribution of the HLA-A,B,C proteins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459235

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Recent advances in immunobiology of brain tumors.

Authors:  M Tada; N de Tribolet
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

2.  Intracerebral inflammatory response to experimental brain contusion.

Authors:  S Holmin; T Mathiesen; J Shetye; P Biberfeld
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

3.  Human neuroblastoma cell growth in xenogeneic hosts: comparison of T cell-deficient and NK-deficient hosts, and subcutaneous or intravenous injection routes.

Authors:  W J Turner; J Chatten; L A Lampson
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

4.  Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.

Authors:  M Maio; M Altomonte; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Lysis of myotubes by alloreactive cytotoxic T cells and natural killer cells. Relevance to myoblast transplantation.

Authors:  R Hohlfeld; A G Engel
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

6.  Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.

Authors:  P Shamamian; M Mancini; Y Kawakami; N P Restifo; S A Rosenberg; S L Topalian
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

7.  Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing.

Authors:  E Katsanis; M A Bausero; H Xu; P J Orchard; Z Xu; R S McIvor; A A Brian; B R Blazar
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

8.  Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells.

Authors:  Avadhut D Joshi; Erin M Clark; Peng Wang; Corey M Munger; Ganapati V Hegde; Sam Sanderson; Harish P G Dave; Shantaram S Joshi
Journal:  J Neuroimmune Pharmacol       Date:  2006-10-10       Impact factor: 7.285

9.  Specific suppression of major histocompatibility complex class I and class II genes in astrocytes by brain-enriched gangliosides.

Authors:  P T Massa
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307

10.  Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma.

Authors:  A Pession; A Prete; F Locatelli; S Pierinelli; A L Pession; R Maccario; E Magrini; B De Bernardi; P Paolucci; G Paolucci
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.